

Key Updates in Bispecific Antibodies in NHL Management—Unmet Needs and Opportunities for Improved Management in Later-Line Management

Toolkit

Overview of B-Cell Non-Hodgkin Lymphomas

Reference	URL
American Cancer Society (ACS). Key statistics for non-Hodgkin lymphoma. 2023.	https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. <i>J Clin Oncol</i> . 1998;16:2780-2795.	https://ascopubs.org/doi/10.1200/JCO.1998.16.8.2780
Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach. <i>Blood</i> . 2005;106:1164-1174.	https://ashpublications.org/blood/article/106/4/1164/21561/Advances-in-the-biology-and-therapy-of-diffuse
Cerhan JR. Epidemiology of Follicular Lymphoma. <i>Hematol Oncol Clin North Am</i> . 2020;34:631-646.	https://www.sciencedirect.com/science/article/abs/pii/S0889858820300265
Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. <i>N Engl J Med</i> . 2002;346:235-242.	https://www.nejm.org/doi/full/10.1056/NEJMoa011795
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. <i>Blood</i> . 2010;116:2040-2045.	https://ashpublications.org/blood/article/116/12/2040/27477/Long-term-outcome-of-patients-in-the-LNH-98-5
Dunleavy K. Aggressive B cell lymphoma: Optimal therapy for MYC-positive, double-hit, and triple-hit DLBCL. <i>Curr Treat Options Oncol</i> . 2015;16:58.	https://link.springer.com/article/10.1007/s11864-015-0374-0
Lynch DT, Koya S, Acharya U, Kumar A. Mantle cell lymphoma. <i>StatPearls</i> . July 28, 2023.	https://www.ncbi.nlm.nih.gov/books/NBK536985/
National Cancer Institute (NCI). Cancer Stat Facts: NHL—Follicular Lymphoma.	https://seer.cancer.gov/statfacts/html/follicular.html
Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. <i>Am J Transplant</i> . 2006;6:859-866.	https://www.amjtransplant.org/article/S1600-6135(22)02663-6/fulltext
Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. <i>N Engl J Med</i> . 2018;378:1396-1407.	https://www.nejm.org/doi/10.1056/NEJMoa1801445

Bispecific Antibodies in B-Cell NHL Therapy: Current State, Future Potential, and Adverse Event Profile

Reference	URL
<p>A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy (Celestimo). ClinicalTrials.gov identifier: NCT04712097. Updated September 6, 2023.</p>	<p>https://classic.clinicaltrials.gov/ct2/show/NCT04712097</p>
<p>A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated (ELM-2). ClinicalTrials.gov identifier: NCT03888105. Updated April 20, 2023.</p>	<p>https://classic.clinicaltrials.gov/ct2/show/NCT03888105</p>
<p>Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. <i>Blood</i>. 2020;136(suppl 1):42-43.</p>	<p>https://www.sciencedirect.com/science/article/pii/S0006497118696065</p>
<p>Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. <i>Lancet Haematol</i>. 2022;9:e327-e339.</p>	<p>https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00072-2/fulltext</p>
<p>Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. <i>J Clin Oncol</i>. 2022;40:481-491.</p>	<p>https://ascopubs.org/doi/10.1200/JCO.21.00931</p>
<p>Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. <i>Lancet Oncol</i>. 2022;23:1055-1065.</p>	<p>https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00335-7/fulltext</p>
<p>Chiu C, Hiemstra IH, Johnson P, et al. Evaluation of pharmacodynamic biomarkers of epcoritamab (GEN3013; CD3XCD20): Results from a phase 1/2 dose-escalation study in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Presented at the 25th Congress of the European Hematology Association; June 11-21, 2020. EHA Library. 2020:EP1330.</p>	<p>https://library.ehaweb.org/eha/2020/eha25th/293817/christopher.chiu.evaluation.of.pharmacodynamic.biomarkers.of.epcoritamab.html</p>
<p>Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. <i>J Clin Oncol</i>. 2015;33:2516-2522.</p>	<p>https://ascopubs.org/doi/10.1200/JCO.2014.59.7534</p>

Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. <i>N Engl J Med.</i> 2022;387:2220-2231.	https://www.nejm.org/doi/10.1056/NEJMoa2206913
Dickinson M, Carlo-Stella C, Morschhauser F, et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results. <i>J Clin Oncol.</i> 2022;40(16 suppl):7500.	https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7500
Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. <i>EBioMedicine.</i> 2020;52:102625.	https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30840-0/fulltext
González Barca E. Role of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma in the CART era. <i>Front Immunol.</i> 2022;13:909008.	https://www.frontiersin.org/articles/10.3389/fimmu.2022.909008/full
Hosseini I, Gadkar K, Stefanich E, et al. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: Impact of translational system modeling. <i>NPJ Syst Biol Appl.</i> 2020;6:28.	https://www.nature.com/articles/s41540-020-00145-7
Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. <i>J Clin Oncol.</i> 2021;39:1959-1970.	https://ascopubs.org/doi/10.1200/JCO.20.03175
Hutchings M, Mous R, Clausen MR, et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: Updated dose escalation data. <i>Blood.</i> 2020;136(suppl 1):45-46.	https://ashpublications.org/blood/article/136/Supplement%201/45/470017/Subcutaneous-Epcoritamab-Induces-Complete
Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study. <i>Lancet.</i> 2021;398:1157-1169.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00889-8/fulltext
Kim TM, Alonso A, Prince M, et al. A phase 2 study of odronextamab (REGN1979), a CD20 x CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood.</i> 2020;136(suppl 1):28-29.	https://ashpublications.org/blood/article/136/Supplement%201/28/472688/A-Phase-2-Study-of-Odronextamab-REGN1979-a-CD20-x
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood.</i> 2014;124:188-195.	https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management
Lee DW, Santomaso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <i>Biol Blood Marrow Transplant.</i> 2019;25:625-638.	https://www.astctjournal.org/article/S1083-8791(18)31691-4/fulltext

Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: Data from the observational National LymphoCare Study. <i>Br J Haematol.</i> 2019;184:660-663.	https://onlinelibrary.wiley.com/doi/10.1111/bjh.15149
Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody. <i>Leuk Lymphoma.</i> 2021;62:3098-3108.	https://www.tandfonline.com/doi/abs/10.1080/10428194.2021.1953016
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphoma. Version 5.2023.	https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. <i>Nat Rev Clin Oncol.</i> 2018;15:47-62.	https://www.nature.com/articles/nrclinonc.2017.148
Nie S, Wang Z, Moscoso-Castro M, et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics. <i>Antib Ther.</i> 2020;3:18-62.	https://academic.oup.com/abt/article/3/1/18/5739255
Phillips T, Dickenson M, Morschhauser F, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. Presented at the 64th ASH Annual Meeting; December 10–13, 2022.	https://medically.gene.com/global/en/unrestricted/haematology/ASH-2022/ash-2022-presentation-phillips-glofitamab-monotherapy-i.html
Phillips T, Dickenson M, Morschhauser F, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. <i>Blood.</i> 2022;140(suppl 1):178-180.	https://ashpublications.org/blood/article/140/Supplement%201/178/489039/Glofitamab-Monotherapy-Induces-High-Complete
Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. <i>Blood.</i> 2019;134(suppl 1):6.	https://ashpublications.org/blood/article/134/Supplement%201/6/427814/Mosunetuzumab-Induces-Complete-Remissions-in-Poor
Smith EJ, Olson K, Haber LJ, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. <i>Sci Rep.</i> 2015;5:17943.	https://www.nature.com/articles/srep17943
Sun LL, Ellerman D, Mathieu M, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. <i>Sci Transl Med.</i> 2015;7:287ra70.	https://www.science.org/doi/10.1126/scitranslmed.aaa4802
Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II Trial. <i>J Clin Oncol.</i> 2023;41:2238-2247.	https://ascopubs.org/doi/10.1200/JCO.22.01725
Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial. <i>Lancet.</i> 2018;391:659-667.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33108-2/fulltext

<p>Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. <i>Blood</i>. 2015;126:739-745.</p>	<p>https://ashpublications.org/blood/article/126/6/739/34612/Long-term-follow-up-of-MCL-patients-treated-with</p>
<p>Wang XV, Hanson CA, Tschumper RC, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. <i>Blood</i>. 2021;138:2810-2827.</p>	<p>https://ashpublications.org/blood/article/138/26/2810/476606/Measurable-residual-disease-does-not-preclude</p>
<p>Zhou K, Zou D, Zhou J, et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: A pooled analysis of two clinical trials. <i>J Hematol Oncol</i>. 2021;14:167.</p>	<p>https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01174-3</p>
<p>Zhu M, Olson K, Kirshner JR, et al. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. <i>Clin Transl Sci</i>. 2022;15:954-966.</p>	<p>https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13212</p>

All URLs accessed September 26, 2023